Board approved audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026, with unmodified audit opinion.
Standalone FY26 net profit increased 31.2% to ₹178.31 crore on revenue growth of 20.7% to ₹765.43 crore.
Completed amalgamation of subsidiary Medinova Diagnostic, issuing 171,792 shares and creating amalgamation reserve.
Board recommended final dividend of ₹2 per share (200%) for FY26, subject to shareholder approval.